![]() |
ArchemixArchemix, a biopharmaceutical company, is leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease. Archemix believes the unique properties of aptamers hold extraordinary potential in the fast-breaking world of drug discovery and development. Because of their unequaled specificity for their molecular targets, aptamers provide a promising alternative to conventional therapeutic approaches in a wide range of disease areas, including many of those currently addressed by protein-based therapeutics. Archemix is leveraging a dominant patent portfolio and proprietary technologies to create a novel class of therapeutics which encompass many of the benefits of small molecule drugs and biotherapeutics. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Recent NewsArchemix and GlaxoSmithKline Form Strategic Alliance To Develop Aptamers to Treat Inflammatory DiseasesNitroMed and Archemix Announce Merger AgreementArchemix Signs Aptamer Therapeutics Agreement with LillyArchemix’ ARC1779 Granted Orphan Designation in EU for the Treatment of TTP, a Life-Threatening Blood DisorderArchemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood DisorderArchemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by NuveloArchemix Announces Initiation of Phase 2a Trial for Aptamer Product Candidate ARC1779 in Patients with Acute Coronary Syndrome |
![]() CEOErrol De Souza, Ph.D.Contact Info300 Third StreetCambridge, Massachusetts 02142 Phone: 617.621.7700 Fax: 617.621.9300 Key LinksWebsiteJobs Highland Team Corey Mulloy
|